Internalization of amyloid-β, mediated by the FcγRIIb2 receptor, is negatively regulated by TOM1, reducing amyloid-β neurotoxicity in AD brains (Gwon et al., 2018). The gene discussed is TOM1; the disease is Alzheimer disease.